ES2752034T3 - Formaciones inyectables de antibiótico y sus procedimientos de uso - Google Patents
Formaciones inyectables de antibiótico y sus procedimientos de uso Download PDFInfo
- Publication number
- ES2752034T3 ES2752034T3 ES13819728T ES13819728T ES2752034T3 ES 2752034 T3 ES2752034 T3 ES 2752034T3 ES 13819728 T ES13819728 T ES 13819728T ES 13819728 T ES13819728 T ES 13819728T ES 2752034 T3 ES2752034 T3 ES 2752034T3
- Authority
- ES
- Spain
- Prior art keywords
- pnt
- compound
- penetamate
- compounds
- hydroiodide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000015572 biosynthetic process Effects 0.000 title description 6
- 238000005755 formation reaction Methods 0.000 title description 6
- 230000003115 biocidal effect Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 99
- 239000000203 mixture Substances 0.000 claims abstract description 54
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims abstract description 44
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims abstract description 13
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims abstract description 13
- 229940093471 ethyl oleate Drugs 0.000 claims abstract description 13
- 239000007927 intramuscular injection Substances 0.000 claims abstract description 6
- 238000010255 intramuscular injection Methods 0.000 claims abstract description 5
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 4
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 4
- 239000004094 surface-active agent Substances 0.000 claims description 28
- 239000003755 preservative agent Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 239000006185 dispersion Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 239000011521 glass Substances 0.000 abstract description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 86
- 239000000725 suspension Substances 0.000 description 57
- 239000003981 vehicle Substances 0.000 description 44
- 229940056360 penicillin g Drugs 0.000 description 41
- 235000019371 penicillin G benzathine Nutrition 0.000 description 39
- 238000009472 formulation Methods 0.000 description 37
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 34
- 235000013336 milk Nutrition 0.000 description 31
- 239000008267 milk Substances 0.000 description 31
- 210000004080 milk Anatomy 0.000 description 31
- 239000003921 oil Substances 0.000 description 28
- 235000019198 oils Nutrition 0.000 description 28
- 238000007918 intramuscular administration Methods 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 235000013773 glyceryl triacetate Nutrition 0.000 description 17
- 239000001087 glyceryl triacetate Substances 0.000 description 17
- 229960002622 triacetin Drugs 0.000 description 17
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 15
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 208000004396 mastitis Diseases 0.000 description 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 14
- 229920000053 polysorbate 80 Polymers 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000004062 sedimentation Methods 0.000 description 12
- 241000283690 Bos taurus Species 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 6
- 229940068968 polysorbate 80 Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000019445 benzyl alcohol Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 4
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 4
- 229940063655 aluminum stearate Drugs 0.000 description 4
- 239000008135 aqueous vehicle Substances 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 239000001692 EU approved anti-caking agent Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000002687 nonaqueous vehicle Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- -1 diethylaminoethyl ester Chemical class 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 229940095783 procaine benzylpenicillin Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- UTSOXZIZVGUTCF-UHFFFAOYSA-N hydrate;hydroiodide Chemical compound O.I UTSOXZIZVGUTCF-UHFFFAOYSA-N 0.000 description 1
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Pregnancy & Childbirth (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ60129912 | 2012-07-17 | ||
| NZ61017513 | 2013-05-03 | ||
| NZ613138A NZ613138B2 (en) | 2013-07-12 | Injectable antibiotic formulations and their methods of use | |
| PCT/NZ2013/000123 WO2014014363A1 (en) | 2012-07-17 | 2013-07-16 | Injectable antibiotic formulations and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2752034T3 true ES2752034T3 (es) | 2020-04-02 |
Family
ID=49949085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13819728T Active ES2752034T3 (es) | 2012-07-17 | 2013-07-16 | Formaciones inyectables de antibiótico y sus procedimientos de uso |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10376585B2 (enExample) |
| EP (1) | EP2874624B8 (enExample) |
| JP (1) | JP6189437B2 (enExample) |
| KR (1) | KR102113822B1 (enExample) |
| CN (1) | CN104470517B (enExample) |
| AU (1) | AU2013290826B2 (enExample) |
| BR (1) | BR112014031083B1 (enExample) |
| CA (1) | CA2875351C (enExample) |
| CL (1) | CL2014003423A1 (enExample) |
| CO (1) | CO7240359A2 (enExample) |
| CR (1) | CR20140550A (enExample) |
| DK (1) | DK2874624T3 (enExample) |
| DO (1) | DOP2014000288A (enExample) |
| ES (1) | ES2752034T3 (enExample) |
| HR (1) | HRP20191730T1 (enExample) |
| HU (1) | HUE046427T2 (enExample) |
| IL (1) | IL236713B (enExample) |
| LT (1) | LT2874624T (enExample) |
| MX (2) | MX387668B (enExample) |
| MY (1) | MY172561A (enExample) |
| NI (1) | NI201400152A (enExample) |
| PH (1) | PH12014502716A1 (enExample) |
| PL (1) | PL2874624T3 (enExample) |
| PT (1) | PT2874624T (enExample) |
| RU (1) | RU2643327C2 (enExample) |
| SI (1) | SI2874624T1 (enExample) |
| SV (1) | SV2014004882A (enExample) |
| UA (1) | UA118654C2 (enExample) |
| WO (1) | WO2014014363A1 (enExample) |
| ZA (1) | ZA201409322B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015014963B1 (pt) * | 2012-12-20 | 2022-04-12 | Alleva Animal Health Limited | Formulação de suspensão injetável veterinária |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE49768B1 (en) | 1979-05-21 | 1985-12-11 | Leo Pharm Prod Ltd | 6beta-halopenicillanic acid derivatives |
| IE51516B1 (en) * | 1980-10-06 | 1987-01-07 | Leo Pharm Prod Ltd | 1,1-dioxapenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate napsylate |
| IL64009A (en) | 1980-10-31 | 1984-09-30 | Rech Applications Therap | Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them |
| IE51846B1 (en) * | 1980-11-17 | 1987-04-15 | Leo Pharm Prod Ltd | Pharmaceutical preparation for veterinary use and an appliance containing it |
| DE3377064D1 (en) | 1982-12-28 | 1988-07-21 | Bayer Ag | Stable aminoglycoside-penicillin injection formulation |
| US5736151A (en) | 1996-12-09 | 1998-04-07 | Pharmacia & Upjohn Company | Antibiotic oil suspensions |
| CH693625A5 (it) * | 1999-02-18 | 2003-11-28 | Inpharma Sa | Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi. |
| US20040022815A1 (en) | 2002-08-05 | 2004-02-05 | Orchid Health Care | Novel pharmaceutical composition of ceftiofur |
| KR20040015622A (ko) | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물 |
| US6911441B2 (en) | 2002-12-16 | 2005-06-28 | Akzo Nobel N.V. | Prolonged release pharmaceutical composition |
| CN1517090A (zh) | 2003-01-20 | 2004-08-04 | 王玉万 | 含抗菌药物的兽用混悬注射剂或乳剂 |
| US20050143347A1 (en) * | 2003-12-22 | 2005-06-30 | Aventis Pharma Deutschland Gmbh | Medicinal lipolysis of accumulations of fat |
| DE102004025324A1 (de) * | 2004-05-19 | 2005-12-08 | Boehringer Ingelheim Vetmedica Gmbh | Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| US8679540B2 (en) * | 2006-06-09 | 2014-03-25 | Flamel Technologies | Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications |
| WO2009052629A1 (en) * | 2007-10-26 | 2009-04-30 | Chemaphor Inc. | Compositions and methods for enhancing immune response |
| PT2294012E (pt) * | 2008-05-07 | 2014-10-15 | Salix Pharmaceuticals Ltd | Administração de um agente de limpeza intestinal e de um antibiótico para o tratamento de doença intestinal |
| US8501800B2 (en) * | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| WO2010138918A1 (en) * | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
| CN101822637A (zh) | 2009-12-31 | 2010-09-08 | 天津瑞普生物技术股份有限公司 | 一种含有β-内酰胺类抗生素的混悬注射剂 |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| DE102010015143A1 (de) | 2010-04-16 | 2011-10-20 | Cts Chemical Industries Ltd. | Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon |
| KR20140047617A (ko) * | 2011-06-23 | 2014-04-22 | 바이엘 뉴질랜드 리미티드 | 마크로사이클릭 락톤 및 레바미솔을 포함하는 항-기생충 조성물 및 기생충 감염의 치료 방법 |
| WO2013095166A1 (en) | 2011-12-23 | 2013-06-27 | Bayer New Zealand Limited | Antibiotic formulations |
| RU2627429C2 (ru) * | 2012-02-27 | 2017-08-08 | Байер Нью Зиленд Лимитед | Составы с контролируемым высвобождением и способы их использования |
-
2013
- 2013-07-16 LT LT13819728T patent/LT2874624T/lt unknown
- 2013-07-16 MX MX2018009121A patent/MX387668B/es unknown
- 2013-07-16 CA CA2875351A patent/CA2875351C/en active Active
- 2013-07-16 ES ES13819728T patent/ES2752034T3/es active Active
- 2013-07-16 SI SI201331584T patent/SI2874624T1/sl unknown
- 2013-07-16 AU AU2013290826A patent/AU2013290826B2/en active Active
- 2013-07-16 RU RU2015105251A patent/RU2643327C2/ru active
- 2013-07-16 KR KR1020157001143A patent/KR102113822B1/ko active Active
- 2013-07-16 MX MX2014015927A patent/MX358248B/es active IP Right Grant
- 2013-07-16 BR BR112014031083-1A patent/BR112014031083B1/pt active IP Right Grant
- 2013-07-16 HU HUE13819728A patent/HUE046427T2/hu unknown
- 2013-07-16 HR HRP20191730 patent/HRP20191730T1/hr unknown
- 2013-07-16 CN CN201380038000.4A patent/CN104470517B/zh active Active
- 2013-07-16 PT PT138197280T patent/PT2874624T/pt unknown
- 2013-07-16 DK DK13819728T patent/DK2874624T3/da active
- 2013-07-16 EP EP13819728.0A patent/EP2874624B8/en active Active
- 2013-07-16 US US14/415,940 patent/US10376585B2/en active Active
- 2013-07-16 WO PCT/NZ2013/000123 patent/WO2014014363A1/en not_active Ceased
- 2013-07-16 MY MYPI2014703596A patent/MY172561A/en unknown
- 2013-07-16 UA UAA201501302A patent/UA118654C2/uk unknown
- 2013-07-16 PL PL13819728T patent/PL2874624T3/pl unknown
- 2013-07-16 JP JP2015523049A patent/JP6189437B2/ja active Active
-
2014
- 2014-12-02 CR CR20140550A patent/CR20140550A/es unknown
- 2014-12-04 PH PH12014502716A patent/PH12014502716A1/en unknown
- 2014-12-17 CL CL2014003423A patent/CL2014003423A1/es unknown
- 2014-12-18 DO DO2014000288A patent/DOP2014000288A/es unknown
- 2014-12-18 ZA ZA2014/09322A patent/ZA201409322B/en unknown
- 2014-12-19 NI NI201400152A patent/NI201400152A/es unknown
- 2014-12-22 SV SV2014004882A patent/SV2014004882A/es unknown
- 2014-12-26 CO CO14284224A patent/CO7240359A2/es unknown
-
2015
- 2015-01-14 IL IL236713A patent/IL236713B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2218705T3 (es) | Composiciones farmaceuticas mejoradas. | |
| KR20190005183A (ko) | 풀베스트란트 제제 및 그의 사용 방법 | |
| ES2392579T3 (es) | Sistemas sinérgicos de mezclas de poloxámeros para la solubilización de fármacos | |
| ES2866636T3 (es) | Composiciones farmacéuticas que comprenden paracetamol y proceso para preparar las mismas | |
| EP3247350B1 (en) | Liquid formulation of cabazitaxel | |
| ES2752034T3 (es) | Formaciones inyectables de antibiótico y sus procedimientos de uso | |
| JP2015526463A (ja) | 改善されたダプトマイシン注射用製剤 | |
| AU2011273064A1 (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
| US9452155B2 (en) | Injectable antibiotic formulations and their methods of use | |
| EP2934524B1 (en) | Penethamate veterinary injectable formulations | |
| TWI631948B (zh) | 可注射型抗生素配方及其使用方法 | |
| NZ613240A (en) | Injectable antibiotic formulations and their methods of use | |
| NZ613240B2 (en) | Injectable antibiotic formulations and their methods of use | |
| NZ613138B2 (en) | Injectable antibiotic formulations and their methods of use | |
| WO2014139677A1 (en) | Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof | |
| MXPA94003569A (en) | Stable quinolone and naphthyridine premix formulations | |
| BR112018072768B1 (pt) | Suspensão, composição farmacêutica, método para formar uma suspensão fulvestrant aquosa e suspensão fulvestrant aquosa | |
| AU2013364500A1 (en) | Veterinary injectable formulations |